WinstonWınston
Eckert & Ziegler SE logo

Eckert & Ziegler SE

EUZ.DE
66
Medical - Specialties · Healthcare
Price
€13.95
-0.19 (-1.34%)
Market Cap
€872.9M
Exchange
Frankfurt Stock Exchange
Winston Score
66
Winston is curious
A decent business — some strong pillars, some weaker.

Eckert & Ziegler is a German company that makes radioactive materials used in medicine and industry. Its main products are radioisotopes — tiny amounts of radioactive substances used to treat cancer, diagnose diseases, and calibrate scientific equipment. Its customers include hospitals, cancer treatment centers, pharmaceutical companies, and research labs around the world.

The company earns money by producing and selling these radioactive materials, along with related devices and services. It operates primarily in Europe and North America, with a growing presence in other markets, and generates roughly €250–300 million in annual revenue. Its moat comes from the highly regulated nature of radioactive material production — getting government licenses to handle and ship these substances takes years, which keeps most competitors out. The key growth driver is the fast-expanding field of radioligand therapy, a cancer treatment method that uses targeted radioactive molecules, where Eckert & Ziegler is positioned as a supplier of critical isotope ingredients.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+7.0% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

+13.3% YoY

YoY Growth Rate

Steady EPS growth

R&D Spend

$0/ year

Declining (-100% vs prior year)

0.0% of revenue

Below sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

35.7%ownership

Rising

Insiders increasing their stake — aligned with shareholders

Cash Position

Cash flow positive

$124M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

Eckert & Ziegler SE is growing revenue at 7% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Share count broadly stable

+0.9% over 4y

The share count has stayed roughly flat over this period — little dilution or buyback activity.

Diluted shares outstanding: 62.3M (2021) → 62.8M (2025)

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
49.4%
Healthy — 49.4% gross margin
Operating Margin
23.5%
Excellent — 23.5% operating margin
ROCE
6.0%
Weak — 6.0% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+6.8%
Slow sales growth (6.8% YoY)
EPS YoY
+27.9%
Earnings growing fast (27.9% YoY)

Earnings growing 25%+ a year. The compounder zone.

EPS Consistency
6/8 quarters
Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
120%
Turns 120% of profit into real cash
FCF Margin
10.2%
Modest free cash flow (10.2%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.06
Conservative — low debt load (0.06)
Interest Cover
33.80x
Comfortably covers interest (33.8x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
19.8x
Fair value — P/E 19.8

P/E in the normal range. Price is roughly $15 for every $1 of yearly profit.

P/E vs Forward
+4.2
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (19.8 → 15.6)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend Yield
1.38%
Small dividend — 1.38% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend Growth
-67.0%
Dividend cut (-67.0% YoY) — warning sign

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial